Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TFMQQ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Turmetabart adizutecan
|
|||||
| Synonyms |
ABBV-706
Click to Show/Hide
|
|||||
| Organization |
AbbVie (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 3
|
|||||
| Drug-to-Antibody Ratio |
6
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-SEZ6 antibody
|
|||||
| Antigen Name |
Seizure protein 6 homolog (SEZ6)
|
Antigen Info | ||||
| Payload Name |
A-1770637
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
BrAc-Val-Ala
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
HY-148820
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Brain cancer |
1 Trials
|
||||||||||
| Lung cancer |
1 Trials
|
1 Trials
|
|||||||||
| Unspecific solid tumor |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
21%
|
|||
| Patients Enrolled |
Eligible participants have ECOG 0-1, adequate organ function, QTc ≤450/470 msec (M/F), and measurable disease (RECIST 1.1/RANO). Parts 1-4 include R/R SCLC/CNS tumors/NECs progressing after SOC. Exclusions: ILD/pneumonitis, prior Top1-ADC therapy, or (Part 2) prior SEZ6-ADC. Fresh/archival tumor tissue is required for SEZ6 analysis.
|
||||
| Administration Dosage |
ABBV-706 was administered IV at 1.3-3.5 mg/kg doses Q3W in 21-d cycles.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05599984 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors | ||||
| Primary Endpoint |
Primary outcomes include AE incidence, PK parameters (Cmax, Tmax, t½, AUC), immunogenicity (ADA/nAb incidence), and tumor response metrics (ORR per RECIST 1.1/RANO, DOR, PFS, OS) assessed over ~2 years. The RP2D will be determined based on safety, PK, and efficacy data.
|
||||
References